Subscribe200$/product give away!

Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

BELVIQ- lorcaserin hydrochloride hemihydrate tabletBELVIQ XR- lorcaserin hydrochloride hemihydrate tablet, film coated, extended release

Patient Information

Advise the patient to read the FDA-approved patient labeling (Patient Information).

  • Inform patients that BELVIQ/BELVIQ XR is indicated for chronic weight management only in conjunction with a reduced-calorie diet and increased physical activity.
  • Caution patients not to increase their dose of BELVIQ/BELVIQ XR.
  • Instruct patients to discontinue use of BELVIQ/BELVIQ XR if they have not achieved 5% weight loss by 12 weeks of treatment.
  • Instruct patients to tell their healthcare provider about all the medications, nutritional supplements and vitamins (including any weight loss products) that they may take while taking BELVIQ/BELVIQ XR.
  • Inform patients of the possibility of serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions with the combined use of BELVIQ/BELVIQ XR with other serotonergic drugs, including selective serotonin-norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs), triptans, drugs that impair metabolism of serotonin (including monoamine oxidase inhibitors [MAOIs]), dietary supplements such as St. John s Wort and tryptophan, tramadol, or antipsychotics or other dopamine antagonists.
  • Inform patients who develop signs or symptoms of valvular heart disease, including dyspnea or dependent edema to seek medical attention.
  • Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that BELVIQ/BELVIQ XR therapy does not affect them adversely.
  • Instruct patients to seek medical attention in the event of emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
  • Instruct men who have an erection lasting greater than 4 hours, whether painful or not, to immediately discontinue the drug and seek emergency medical attention.
  • Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider with a known or suspected pregnancy[see Contraindications (4), Use in Specific Populations (8.1)].
  • Advise women to avoid use of BELVIQ/BELVIQ XR while breastfeeding[see Use in Specific Populations (8.2)].

Distributed by Eisai Inc., Woodcliff Lake, NJ 07677


Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources
2017 © Copyright PharmacyHQ.com. Questions?
Please contact: phq.contact@gmail.com